Please try another search
For the three months ended 31 March 2020, Progenics Pharmaceuticals, Inc. revenues increased 46% to $6.2M. Net loss decreased 10% to $16.8M. Revenues reflect Royalty income increase of 15% to $4.8M. Lower net loss reflects Research & Development decrease of 17% to $9.9M (expense), Change in contingent consideration liabi decrease from $900K (expense) to $300K (income), Stock-based Compensation in SGA decrease of 38% to $391K (expense).
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Total Revenue | 6.25 | 15.13 | 5.61 | 9.97 |
Gross Profit | 4.69 | 13.77 | 4.3 | 9.47 |
Operating Income | -15.89 | -10.71 | -18.12 | -19.09 |
Net Income | -16.8 | -11.28 | -18.84 | -19.7 |
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Total Assets | 98.34 | 119.47 | 130.05 | 152.78 |
Total Liabilities | 67.73 | 72.92 | 74.11 | 80.05 |
Total Equity | 30.61 | 46.55 | 55.94 | 72.73 |
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -7.61 | -74.7 | -55.87 | -38.7 |
Cash From Investing Activities | -3.55 | -15.51 | -12.74 | -10.1 |
Cash From Financing Activities | -1.52 | -3.9 | -2.57 | -2.32 |
Net Change in Cash | -12.88 | -94.16 | -71.4 | -51.12 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review